Radical Prostatectomy for Clinical Stage T3a Disease
Overview
Affiliations
Background: Men with clinical stage T3a disease are at high risk and are often encouraged to undergo radiation therapy with concomitant hormonal therapy. The long-term outcomes among men treated with radical prostatectomy for clinical stage T3a disease were examined.
Methods: Among 3397 men treated by radical prostatectomy by 1 surgeon between 1987 and 2003, 62 (1.8%) men were identified who had clinical stage T3a disease. Among the 56 men not treated with neoadjuvant or adjuvant therapies before prostate-specific antigen (PSA) recurrence, the long-term outcomes of PSA-free survival, metastasis-free survival, and prostate cancer specific survival were examined. Median and mean follow-up after surgery were 10.3 and 13 years, respectively (range, 1-17).
Results: Ninety-one percent of men in this group had pathological T3 disease. PSA-free survival at 15 years after surgery was 49%. Metastasis-free survival and cause-specific survival at 15 years after surgery were 73% and 84%, respectively. Among men with a PSA recurrence, 46% received secondary therapy before metastasis. The only preoperative or pathological feature that predicted risk of prostate cancer death was lymph node metastasis (hazard ratio [HR]: 9.22, 95% confidence interval [CI]: 1.06-80.02, P = .044). Among the 28 men with a PSA recurrence, PSA doubling time (PSADT) data were available for 23, of which 11 (48%) has a PSADT >/=9 months. No patient with a PSADT >/=9 months died of prostate cancer. A PSADT <9 months was significantly associated with increased risk of prostate cancer death (log-rank, P = .004).
Conclusions: In a select cohort of men with clinical stage T3a disease, radical prostatectomy alone provides long-term cancer control in about half of the men and results in a prostate cancer-specific survival of 84%. Among men with a PSA recurrence, PSADT at the time of recurrence is a useful determinant of risk of prostate cancer death.
El-Karak F, Shamseddine A, Omar A, Haddad I, Abdelgawad M, Naqqash M Ecancermedicalscience. 2024; 18:1695.
PMID: 38774566 PMC: 11108050. DOI: 10.3332/ecancer.2024.1695.
Sugino F, Nakane K, Kawase M, Ueda S, Tomioka M, Takeuchi Y Life (Basel). 2023; 13(5).
PMID: 37240717 PMC: 10223720. DOI: 10.3390/life13051072.
Sjoberg H, Philippou Y, Magnussen A, Tullis I, Bridges E, Chatrian A Br J Cancer. 2021; 125(4):534-546.
PMID: 34155340 PMC: 8367986. DOI: 10.1038/s41416-021-01450-6.
Deng Y, Bi R, Zhu Z, Li S, Xu B, Rather W Oncol Lett. 2019; 18(2):1057-1070.
PMID: 31423166 PMC: 6607368. DOI: 10.3892/ol.2019.10461.
Jang T, Patel N, Faiena I, Radadia K, Moore D, Elsamra S Cancer. 2018; 124(20):4010-4022.
PMID: 30252932 PMC: 6234085. DOI: 10.1002/cncr.31726.